Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15143387 | 0.85 | NOTUM (0.33) | NOTUM | |
| SCHEMBL22508465 | 0.83 | ALDH1A1 (0.46) | CHRNB2CHRNA4ALDH1A1GAADRD2 | |
| SCHEMBL29604062 | 0.81 | SLC6A2 (0.33) | NOTUM | |
| SCHEMBL20907812 | 0.78 | ALDH1A1 (0.33) | NOTUMCHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL20101877 | 0.78 | NOTUM (0.33) | NOTUMCHRNB2CHRNA4DRD2 | |
| SCHEMBL22508367 | 0.78 | NOTUM (0.33) | NOTUMCHRNB2CHRNA4DRD2 | |
| SCHEMBL22415119 | 0.78 | NOTUM (0.33) | NOTUMCHRNB2CHRNA4DRD2 | |
| SCHEMBL16385897 | 0.73 | ALDH1A1 (0.36) | NOTUMALDH1A1GAA | |
| SCHEMBL10444631 | 0.70 | HTR2A (0.38) | NOTUMALDH1A1GAADRD2 | |
| SCHEMBL22415121 | 0.68 | NOTUM (0.30) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2020205832-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205835-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177487-A1 | FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORS | PDXK, PNPO, CDKN1A | NOTUM 2882/4885CHRNB2 4550/4885CHRNA4 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.